Appointment of Dr. Goessens-Rueck strengthens
management team and fulfils commitment to promote female leadership
in biotech
VANCOUVER, Nov. 06, 2018 /CNW/ - RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"),
a company developing next-generation technologies in aesthetics and
orthopedics, announces the appointment of European Clinical and
Regulatory Affairs expert, Dr. Petra
Goessens-Rueck, as Head of Clinical and Regulatory
Affairs.
Dr. Petra Goessens-Rueck has been
a valuable consultant to RepliCel since its inception assisting
with research, development, clinical and regulatory strategy in
addition to managing regulatory submissions and most aspects of the
Company's clinical trials. Dr. Goessens-Rueck is a biotech
consultant with more than 10 years' in-depth experience in the
development of innovative cellular therapeutics. She graduated with
her Doctorate at the Institute of Pharmacology and Toxicology of
Justus-Liebig University of Giessen,
Germany in 1996, followed by a post-doctorate research
fellowship with INSERM in Paris at
their Department of Experimental Medicine. Her work experience
includes industry leaders such as Pfizer and Ratiopharm. Since
2012, Dr. Goessens-Rueck has been recognized as one of Europe's leading consultants for advanced
therapies and medicine products (ATMPs).
"This appointment of Dr. Goessens-Rueck is official recognition
of the role Petra has played and will continue to perform with the
Company," stated RepliCel President & CEO, R. Lee Buckler. "While she will remain as an
independent consultant to the Company and others in the sector,
Petra is a key part of RepliCel's management team. Her appointment
is also an example of RepliCel's commitment to fulfill its part in
the industry's promise to promote female leadership in the
industry."
Dr. Goessens-Rueck will report directly to the RepliCel's Chief
Medical Officer, Dr. Rolf Hoffmann,
and President/CEO, Lee Buckler. She
will be responsible for contributing to and executing RepliCel's
clinical and regulatory strategy and being the primary
clinical/regulatory interface between the Company and its clinical
research organizations, clinical trial sites, and principle
investigators, as well as the Company's clinical development
partners, Shiseido and YOFOTO.
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing cell therapies
for aesthetic and orthopedic conditions affecting what the Company
believes is approximately one in three people in industrialized
nations, including aging/sun-damaged skin, pattern baldness, and
chronic tendon degeneration. These conditions, often
associated with aging, are caused by a deficit of healthy cells
required for normal tissue healing and function. The Company's
product pipeline is comprised of RCT-01 for tendon repair, RCS-01
for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is
currently being co-developed with, and under exclusive license by,
Shiseido for certain Asian countries. All product candidates are
based on RepliCel's innovative technology, utilizing cell
populations isolated from a patient's healthy hair follicles.
RepliCel has also developed a proprietary injection device, RCI-02,
optimized for the administration of its products and licensable for
use with other dermatology applications. Please
visit www.replicel.com for additional information.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/replicel-life-sciences-appoints-head-of-clinical-and-regulatory-affairs-300742526.html
SOURCE RepliCel Life Sciences Inc.
